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Abstract
Prostate cancer is one of the leading causes of cancer death among men worldwide. In this study, using transgenic
adenocarcinoma of mouse prostate (TRAMP) mice, the effect of diet enriched with 1% w/w ursolic acid (UA) was
investigated to evaluate the stage specific chemopreventive activity against prostate cancer. We found that TRAMP mice
fed with UA diet for 8 weeks (weeks 4 to 12) delayed formation of prostate intraepithelial neoplasia (PIN). Similarly, mice fed
with UA diet for 6 weeks (weeks 12 to 18) inhibited progression of PIN to adenocarcinoma as determined by hematoxylin
and eosin staining. Finally, TRAMP mice fed with UA diet for 12 weeks (weeks 24 to 36) demonstrated markedly reduced
tumor growth without any significant effects on total body weight and prolonged overall survival. With respect to the
molecular mechanism, we found that UA down-regulated activation of various pro-inflammatory mediators including, NF-
kB, STAT3, AKT and IKKa/b phosphorylation in the dorsolateral prostate (DLP) tissues that correlated with the reduction in
serum levels of TNF-a and IL-6. In addition, UA significantly down-regulated the expression levels of cyclin D1 and COX-2
but up-regulated the levels of caspase-3 as revealed by immunohistochemical analysis of tumor tissue sections. Finally, UA
was detected in serum samples obtained from various mice groups fed with enriched diet in nanogram quantity indicating
that it is well absorbed in the GI tract. Overall, our findings provide strong evidence that UA can be an excellent agent for
both the prevention and treatment of prostate cancer.
Citation: Shanmugam MK, Ong TH, Kumar AP, Lun CK, Ho PC, et al. (2012) Ursolic Acid Inhibits the Initiation, Progression of Prostate Cancer and Prolongs the
Survival of TRAMP Mice by Modulating Pro-Inflammatory Pathways. PLoS ONE 7(3): e32476. doi:10.1371/journal.pone.0032476
Editor: Ganesh Chandra Jagetia, Mizoram University, India
Received July 8, 2011; Accepted January 28, 2012; Published March 12, 2012
Copyright:  2012 Shanmugam et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from National Medical Research Council of Singapore [R-184-000-168-275 and R-184-000-201-275] to GS. APK was
supported by grants from the National Medical Research Council of Singapore [Grant R-713-000-119-275] and Cancer Science Institute of Singapore, Experimental
Therapeutics I Program [Grant R-713-001-011-271]. KMH was supported by a grant from the National Medical Research Council of Singapore, Biomedical Research
Council of Singapore, and the Singapore Millennium Foundation. The funders has no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: phcgs@nus.edu.sg (GS); cmrhkm@nccs.com.sg (KMH)
Introduction
Prostate cancer is the second leading cause of cancer-related
death among men in Western countries after lung cancer [1].
Chronic inflammation is increasingly being recognized as a
mediator for many cancers [2,3,4] and considerable evidence
suggests that it plays a major role both in the development and
progression of prostate cancer [5]. First, patients with symptomatic
prostatitis are more susceptible to developing prostate cancer.
Second, prostate cancer has been associated with sexually
transmitted infections. Third, decreased risk of prostate cancer is
linked with increased intake of fruits and vegetables, antioxidants,
and non-steroidal anti-inflammatory drugs (NSAID) [6,7]. Fourth,
normal prostate undergoes proliferative inflammatory atrophy
(PIA) before forming prostate intraepithelial neoplasia (PIN), the
precursor of prostate cancer [8]. Fifth, PIA can overexpress
inflammatory enzyme COX-2 [9]. Sixth, the transcription factors
NF-kB and STAT3, both major mediator of inflammation, are
constitutively active in prostate cancer tissues [10]. And seventh,
NF-kB-regulated inflammatory cytokines such as interleukin (IL)-6
is an autocrine growth factor known to be secreted by prostate
cancer tissues [11,12]. Therefore, it is reasonable to suggest that
agents that can suppress inflammatory mediators have a potential
for both the prevention and treatment of prostate cancer.
UA (3b-hydroxy-urs-12-en-28-oic acid), a pentacyclic triterpe-
noid derived from berries, leaves, flowers, and fruits of medicinal
plants, such as Rosemarinus officinalis, Eriobotrya japonica, Calluna
vulgaris, Ocimum sanctum, and Eugenia jumbolana is one such agent that
has been extensively studied for its anti-inflammatory and
anticancer activities in the past decade [13]. UA has been
reported to suppress the proliferation of a variety of tumor cells, to
induce apoptosis, and to inhibit tumor promotion, metastasis, and
angiogenesis [14,15,16,17]. Our group is currently investigating
the unexplored potential of UA for the prevention and treatment
of prostate cancer and has recently reported in two separate
studies that UA can indeed suppress the growth of prostate
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modulating the CXCR4/CXCL12 signaling cascade [18,19].
The transgenic adenocarcinoma of mouse prostate (TRAMP)
model of prostate cancer is based on a transgene consisting of
probasin (PB) promoter-driven SV40 T antigen (Tag) expression.
This transgenic mouse is preferable to implantation models
because in this model prostate cancer spontaneously develops
through a series of well-defined stages. They exhibit remarkable
similarities to human prostate cancer progression from the PIN
stage to invasive adenocarcinoma that metastasizes to liver, lung
and GI tract via activation of a transgene that is hormonally
regulated by androgens [20,21]. Moreover, all TRAMP mice
develop well-differentiated carcinoma (WDC) between 8–12 weeks
of age and metastases to distant sites between 18 and 24 weeks of
age [22]. In the present study, we investigated the potential effects
of UA enriched diet in preventing the development, progression as
well as overall survival of tumors in TRAMP mice. Our data
clearly indicates for the first time that feeding mice with a diet rich
in UA can significantly inhibit the progression from PIN to
adenocarcinoma, and tumor growth. It can also prolong the
survival of mice through the modulation of multiple signaling
cascades.
Results
The present study was designed to investigate the potential
effect(s) of UA on early tumor development, tumor progression
and the overall survival of TRAMP mice (Fig. 1A).
UA suppresses prostatic intraepithelial neoplasia (PIN)
formation
It has been reported previously that TRAMP mice exhibit
increased epithelial stratification in the dorsolateral prostate,
epithelial cells with variably elongated nuclei with condensed
chromatin with flat patterns of low-grade (LG) PIN (LG-PIN) by
4–8 weeks of age and tufted micropapillary and a cribriform
pattern of HG-PIN by 6–10 week of age [22].To investigate if UA
suppresses PIN formation, 4-week-old mice were fed with UA (1%,
w/w) containing diet for 8 weeks and sacrificed at 12 weeks of age
(Group 1). The wet weight of the prostate with seminal vesicles did
not appreciably change in both the control and UA fed TRAMP
mice (data not shown). Visual examination of the abdominal cavity
also did not reveal unusual enlargement of the seminal vesicles,
prostatic lobes or pelvic lymph nodes. Consumption of UA
enriched diet was well tolerated without evidence of toxicity in
terms of animal appearance, behavior and body weight.
While non-TRAMP mice did not show any PIN formation
(Fig. 1B, i), TRAMP mice animals showed LG- and HG-PIN and
well differentiated carcinoma (WDC) (Fig. 1B, ii and iii). The
effects of UA-treatment on the formation of PIN are shown in
Fig. 1C. LG-PIN was seen in 60% of UA-treated mice compared
to 40% in controls while HG-PIN was seen in 20% of UA-treated
mice as opposed to 80% in controls. This demonstrated that UA
treatment had reduced the formation of PIN as well as delayed the
progression from LG- to HG-PIN. In addition, only one animal
showed moderately (MDC) or poorly differentiated carcinoma
(PDC) at this stage. These data strongly suggest that UA has the
potential to be used as a chemopreventive agent.
UA prevents the progression from PIN to prostate cancer
To determine whether or not UA can prevent progression from
PIN to prostate cancer, 12-weeks-old TRAMP-mice were fed with
control or UA (1%, w/w) enriched diet for 6 weeks and then
sacrificed at 18 weeks (Fig. 1A, Group 2). At 18 weeks of age, the
DLP of TRAMP mice exhibited higher incidence of LG-PIN,
HG-PIN, WDC and MDC (Fig. 2A, i & ii) when compared to
those observed at younger ages (Fig. 1B & C). No significant
changes in appearance, body weight and food consumption were
observed between Group 2 mice and their controls. However,
there was an appreciable but statistically insignificant decrease in
the wet weight of prostate gland with the seminal vesicles in UA
fed mice (data not shown). UA-treatment reduced the incidence of
LG-PIN by 60%, HG-PIN by 40% and WDC by 40% (Fig. 2A,
iii).Overall, there was a noticeable shift towards the higher
incidences of non-cancerous DLP in UA-treated mice.
UA suppresses the growth of established prostate cancer
in vivo
To determine if UA can suppress the growth of established
prostate cancer, 24-week-old TRAMP-mice were fed with a
control or UA (1%, w/w) enriched diet for 12 weeks and then
sacrificed at the 36 weeks (Fig. 1A, Group 3). At this age, visual
examination of the abdominal cavity clearly revealed enlarged
seminal vesicles, DLP and other prostate lobes in the control
TRAMP-mice. The DLP showed higher incidence of WDC,
MDC and PDC when compared to those observed at younger
ages, suggesting that a majority of the animals had cancerous
lesions in the DLP (Fig. 2B, i & ii). In contrast, UA–treated
TRAMP mice showed reduced incidence of HG-PIN by 40%,
WDC by 60%, MDC by 40%, and PDC by 20% (Fig. 2B iii).
Overall, the results indicated that UA-treated mice showed non-
cancerous lesions ranging from LG-PIN and HG-PIN to normal
stroma compared to 100% incidence of prostate cancer in control
TRAMP mice.
UA inhibits the activation of AKT, IKKa/b, NF-kB and
STAT3 in DLP of TRAMP mice
We have recently reported that UA can inhibit AKT, IKKa/b,
NF-kB and STAT3 activation in androgen dependent and
independent prostate cancer cell lines [18]. In this study, we
further examined the effects of UA enriched diet on the activation
of pro-inflammatory mediators in the DLP of TRAMP mice
(Fig. 1A). As shown in Fig. 2C, progressive increase in the phospho
(p) -AKT, -pIKKa/b, pSTAT3, and p65 expression were
observed from Group 1 to Group 3 TRAMP mice as the cancer
gradually progressed from LG-PIN formation in group 1 at 4–12
week of age, HG-PIN and WD carcinoma in DLP in group 2 at
12–18 week of age, and WDC, MDC and PDC at 24–36 week of
age. Age-matched non-TRAMP C57BL/6 mice, used as negative
controls, did not show any change in the levels of these
proinflammatory proteins. Interestingly, we observed that UA
treatment resulted in approximately 40–50% inhibition in the
expression of these phosphorylated proteins in the DLP of group 2
and group 3 as compared to untreated TRAMP mice, while only a
slight decrease was observed in group 1 (Fig. 2C). The levels of the
non-phosphorylated AKT and IKKa were minimally affected by
UA-treatment (Fig. 2C). Taken together, our data clearly indicated
that the suppression of pro-inflammatory AKT, NF-kB and
STAT3 activation plays a role in the inhibition of the progression
of prostate cancer in TRAMP mice by UA.
UA inhibits serum TNF-a and IL-6 levels in TRAMP mice
TNF-a and IL-6 are pro-inflammatory cytokines, and are
considered as major biomarkers of inflammation. Groups 1, 2 and
3 mice together with their controls were sacrificed at the end of
each treatment protocol; blood was collected via cardiac puncture.
The serum obtained was evaluated for the levels of TNF-a and IL-
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Group 1 to Group 3 corresponding to increasing age and stages of
cancer progression (Fig. 3A). UA-treatment significantly decreased
serum TNF-a in Group 2 (by ,90%) Group 3 (,30%) (Fig. 3A, i)
as well as serum IL-6 in all three groups by ,40–90% (Fig. 3A, ii).
UA suppresses the expression of cyclin D1, COX-2 and
Caspase-3 in DLP of TRAMP mice
We next investigated various gene products involved in cancer
progression (COX-2), proliferation (cyclin D1) and apoptosis
(caspase-3) by immunohistochemistry in the DLP of Group 3
Figure 1. Schematic diagram showing the experimental design to study the stage specific effects of UA treatment on prostate
tumor progression. A, Male TRAMP-mice 4 weeks of age were fed with UA enriched diet for 8 weeks (Group 1); 12 weeks old mice for 6 weeks
(Group 2); and 24 weeks old mice for 12 week (Group 3). Mice were sacrificed at the end of the treatment periods. Age-matched control TRAMP-mice
received normal diet for the same time periods. For survival studies, Groups 1 to 3 were similarly treated while Group 4 was fed with UA enriched diet
for 36 weeks starting at 4 weeks of age. B, H&E stained sections of DLP of non-TRAMP prostate (i), Group 1 control (ii), and UA-treated (iii) TRAMP
prostate. C, Bar chart shows the incidence of LG-PIN, HG-PIN, WDC, MDC and PDC in DLP of control and Group 1 mice. A slight increase in LG-PIN and
a decrease in HG-PIN were observed (n=5) after UA treatment. No MDC and PDC were observed in Group 1 and corresponding controls. Arrow
indicates LG-PIN; notched right arrow indicates HG-PIN.
doi:10.1371/journal.pone.0032476.g001
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number of cells stained positive for cyclin D1 from 31% to 3% and
COX-2 from 89% to 27%. As expected, the expression of caspase-
3 increased from 6% to 95%. These results clearly indicated that
inhibition of multiple gene products involved in tumor progression
and the induction of apoptosis contribute to the potent anti-tumor
activities of UA as observed in TRAMP tumor tissues.
UA suppresses tumor growth and increases the survival
of TRAMP mice
To determine if UA can suppress the growth of established
prostate cancer, 24-week-old TRAMP-mice were fed with a
control or UA (1%, w/w) enriched diet for 12 weeks and then
sacrificed at the 36 weeks (Fig. 1A, Group 3). The wet weight of
the prostate with seminal vesicles showed significant differences in
Figure 2. Hematoxylin and Eosin stained dorso lateral prostate of TRAMP mice. A, H&E stained section of DLP of Group 2 control (i) and
UA-treated (ii) TRAMP prostate. Arrow indicates LG-PIN, notched right arrow indicates HG-PIN, and block right arrow indicates WDC. (iii) Bar chart
shows the incidence of LG-PIN, HG-PIN, WDC, MDC and PDC in DLP of control and Group 2 mice. Reductions in PIN, WDC and MDC were observed
after UA treatment. B, H&E stained section of DLP of Group 3 control (i) and UA-treated (ii) TRAMP prostate. As described in A; Arrow head indicates
MDC and chevron indicates PDC. C, Western blot of pSTAT3, pAKT, pIKKa/b, and p65 proteins in DLP in Groups 1, 2 and 3 mice. DLP lysates was
prepared and immunoblotting was performed as described in Materials and Methods. Equal protein loading for pAKT and pIKKa/b was determined
by stripping and probing for total AKT and IKKa, p65 and STAT3 blots were stripped and reprobed for b-actin to determine equal protein loading. The
band density was quantitated using Image J software. NT=non-TRAMP-mice; T=TRAMP controls; T+UA=UA-treated TRAMP-mice.
doi:10.1371/journal.pone.0032476.g002
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difference in the tumor volume was observed in the UA-treated
mice (Fig. 4A). We also found that the long term feeding of UA
enriched diet is safe without any organ or tissue toxicity with
minimal effect on body weight (Fig. 4B). Throughout the 36 weeks
period, age matched non-transgenic C57BL/6 mice was used as a
negative controls,which showednone ofthe featuresassociatedwith
prostate cancer observed in TRAMP mice. All data presented on
the effects of UA-treatment in TRAMP mice (Groups 1 to 3) are
consistent with the survival data indicating that such treatment can
significantly prolong the life span of mice (Fig. 4C). In addition to
Groups 1, 2 and 3, a 4th group of TRAMP-mice were fed with the
UA enriched diet for 36 weeks from 4 weeks of age (Group 4);
control groups received normal diet (Fig. 1A). Mice were scored at
the time of death based on tumor burden. Kaplan-Meier survival
plots were generated to determine the overall survival. Log-rank
(Mantel-Cox) plots showed increases in the overall survival of mice
in all UA-treated groups. Median survival of mice in the control
group was 55 weeks, compared to 75 weeks for Group 1 and Group
2, and 72 weeks for Group 4 (P,0.05). In group 3, the median
survival was 68 weeks but failed to reach statistical significance
(Fig.4C). Therefore,itmaybeconcluded that UA-treatmentismost
effective when it was commenced early when the TRAMP-mice
showed no cancer or only early stages of PIN development.
Detection of UA in serum
UA was detected in serum of all 3 groups of TRAMP-mice fed
with UA enriched diet. The concentrations detected varied from
about 600 to 1300 ng/ml with no statistical significance between
groups (Fig. 5B). As UA serum levels were expected to have
reached steady state concentration in all three groups, the
differences in concentration thus reflected individual variations.
No additional peaks were detected in the serum, indicating that
UA does not generate any metabolites (Fig. 5A, iii and iv). Our
study presents the first experimental evidence that UA is well
absorbed after oral feeding and the serum concentrations attained
are sufficient to elicit biological effects as evident by the inhibition
of prostate tumor growth in TRAMP mice.
Figure 3. Enzyme linked immunosorbent assay. A. Suppression of serum TNF-a (i) and IL-6 (ii) by UA-treatment. Groups 1–3 mice were treated
as described in Materials and Methods. Sandwich ELISA assay was performed as per manufacturers’ instruction (R&D systems, USA) to determine the
levels of TNF-a and IL-6. *Statistical significance (P,0.05). B, Immunohistochemical analysis of cyclin D1, caspase 3 and COX-2 in tumor tissues in
Group 3 TRAMP mice. DLP tumor tissues, embedded in paraffin blocks, were cut into 5 mM tissue sections and probed for cyclin D1, caspase 3 and
COX-2 immunoreactivities as described in the Materials and Methods. UA-treatment (1% w/w) decreased the expression of cyclin D1 and COX-2 but
increased caspase-3 expression when compared to controls. Images were taken using a Olympus BX51 microscope (magnification, 206). Positive cells
(brown) were quantitated using The Image-Pro plus v6.3 software package (Media Cybernetics, Inc.).
doi:10.1371/journal.pone.0032476.g003
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The TRAMP mouse model is a well established spontaneously
developing prostate cancer model that mimics natural prostate
tumor progression, from PIN to highly invasive metastatic prostate
cancer [20] in humans. In TRAMP mice, tumor originates from
both DLP and ventral prostate (VP) as a result of Tag expression
that is primarily restricted to the prostatic lobes [22], while human
prostate cancer originates from the peripheral zone that is similar
to the DLP in mice [23]. The anticancer effects of various
chemopreventive agents, including oleanolic acid analogs, sulfo-
raphane, polyphenols obtained from green tea, garlic constituents,
curcumin, 3, 39-diindolylmethane and genistein have been
evaluated previously on spontaneously developing prostate
tumorigenesis in TRAMP mice [24,25,26]. In addition, lycopene,
c-tocopherol, silbinin and tomato enriched diet have all been
found to increase survival and delay the progression from PIN to
adenocarcinoma and decrease the incidence of poorly differenti-
ated carcinoma [23,27,28,29,30]. However, chemoprevention
study with UA in prostate cancer model has not been carried
out previously, and only our group has recently reported for the
first time that UA enriched diet can indeed inhibit prostate tumor
metastasis by modulating the CXCR4/CXCL12 axis in TRAMP
mice [19]; although the effect of UA on tumor development and
progression was not evaluated. In the present study, we studied the
effect of UA treatment at three different stages of cancer
development in TRAMP mice. We found that UA can
significantly inhibit cancer development and progression at all
three stages. In Group 1 mice, we observed measurable
suppressive effects of UA on the PIN development, while in
Group 2 mice, development of high grade PIN was inhibited as
Figure 4. UA inhibits tumor growth in Group 3 TRAMP mice. A,
Mice were euthanized at 36 weeks and the tumor volume was
measured as described in Material and Methods. Error bars represent
SEM. * Statistical significance (P,0.05). B, Body weight of Groups 1–3
TRAMP mice and their controls. C, The effect of UA-treatment on the
long term survival of TRAMP mice. Kaplan-Meier survival analysis was
performed for the control and UA-treated TRAMP mice. Median survival
time was 55 weeks for control (n=5). Median survival time for group 1,
group 2, group 3 and group 4 was 75, 75, 68, and 72 weeks,
respectively. Overall significance was determined using log-rank
(Mantel-Cox) test. UA enriched diet significantly prolonged survival.
doi:10.1371/journal.pone.0032476.g004
Figure 5. Mass spectrometric analysis of UA in serum. A, (i) Ion
chromatograms of serum extracts from mice that had not received UA
(blank). (ii) Full scan spectrum showing the m/z peak with a molecular
mass of 469 corresponds to internal standard (IS) glycyrrhetinic acid. (iii)
Full scan spectrum showing the m/z peak with a molecular mass of
standard UA at 455 and IS at 469 and (iv) Full scan spectrum of sample,
retention time was 1.7 and 1.96 min respectively for both IS and
sample. The chromatograms are representative of 3 independent
experiments. B, Serum concentrations of UA was calculated using
Analyst software 1.4.2 from the linear regression equation of the peak
area ratio against the concentration of the calibration curve. Error bars
represent SEM.
doi:10.1371/journal.pone.0032476.g005
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UA significantly inhibited the progression of preneoplastic PIN in
DLP and tumor volume with no observable adverse effects in the
Group 3 mice. The development of an abundance of non-
cancerous lesions in this group as opposed to the predominance of
cancerous lesions in control TRAMP mice is evident. Results of
histological grading further suggested that UA can predominantly
inhibit the development of precancerous lesions in a majority of
mice, and thus prevent the development of highly invasive
malignant lesions. UA also significantly increased overall survival
by as much as 20 weeks, delayed progression from PIN to
adenocarcinoma, and decreased the incidence of PDC.
Furthermore, we observed that the anti-proliferative and pro-
apoptotic effects of UA are associated with the suppression of cyclin
D1 and COX-2 and the inhibition of NF-kB, STAT3, AKT and
IKKa/b activation in the prostates of TRAMP mice. Such
inhibition correlated with the length of feeding period as evident
by substantially greater inhibition in Group 3 mice, which received
UA continuously for12 consecutive weeks. The reduction in TNF-a
and IL-6 levels also correlated with the length of treatment period.
The suppression of cyclin D1 and COX-2 may well be a
consequence of the reduced activation of NF-kB and STAT3 as
these pro-inflammatory transcription factors regulate the expression
of cyclin D1 and COX-2 [2,3,31]. Increased caspase-3 expression is
indicative of apoptosis. Taken together, these results clearly suggest
that inhibition of cell proliferation and increase in apoptosis play a
pivotal role in UA-mediated inhibition of prostate tumor progres-
sion in TRAMP mice. The fact that UA was detected in all serum
samplesin significant concentrations furtherindicate that UA is well
absorbed and oral feeding can be considered as a preferred route of
administration for a potential chemopreventive and therapeutic
agent for prostate cancer. Therefore, it may be concluded that UA-
treatment inhibited the progression of PIN to adenocarcinoma,
reduced tumor growth and also prolonged the survival of mice.
Together, these results indicate that UA may have a tremendous
potential for use as a chemopreventive agent as well as a promising
agent for prostate cancer treatment.
In summary, our data clearly demonstrate that UA feeding
delays the progression of prostate cancer in mice through the
modulation of various pro-inflammatory molecules. Because
TRAMP is a spontaneous model for prostate cancer that closely
mimics progressive forms of human disease, the results of this
study provide a sound basis for pursuing further studies on the use
of UA either alone or in combination with other therapy for the
prevention and/or treatment of prostate cancer.
Materials and Methods
Reagents
UA (98% pure) was purchased from Guangxi Changzhou
Natural Products Development Company Ltd (China). UA was
mixed with normal mouse diet at 1% w/w and stored at 4uC. Tris,
glycine, NaCl, SDS, glycyrrhetinic acid and b-actin antibody were
purchased from Sigma-Aldrich (St. Louis, MO, USA) and HRP-
conjugated secondary antibody was obtained from Invitrogen
(Carlsbad, CA, USA). Antibodies against phospho-STAT3 (Tyr
705), phospho-AKT (Ser 473), STAT3 were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies to AKT,
p65, phospho-specific IKKa/b (Ser 180/Ser 181), and IKKa
were purchased from Cell Signaling Technology (Beverly, MA).
TNF-a and IL-6 ELISA kits were purchased from Research
Instruments (MA, USA). Bradford reagent was purchased from
Bio-Rad (Hercules, CA). Immunohistochemistry staining kit was
purchased from Dako (Denmark).
TRAMP mice breeding and genotyping
Animal experiments were conducted in accordance with
Singapore NACLAR guidelines (Law as of November 2004) for
laboratory animal use and care and approved by NUS
Institutional Animal care and Use Committee protocol number
052/09. Briefly, 4-week-old TRAMP female mice purchased from
The Jackson Laboratory were mated with C57BL/6 male at NUS
CARE (Singapore). The pups were genotyped for the transgene
(Tag) at 3 weeks of age; DNA was extracted from the tail snips
using TRIZOLH reagent (Invitrogen, USA) and quantified using
Nanodrop spectrophotometer (Thermo scientific, USA). One mg
of the DNA was taken for PCR analysis. Polymerase chain
reaction (PCR) reaction mixture contained 10 mlo f5 6QIAGEN
PCR buffer, 1 mg of DNA, 0.6 mM each of forward and reverse
primers, 2 ml of dNTP mix and 1 ml of Taq polymerase enzyme in
a final volume of 50 ml. Primers used for genotyping, forward
primer: 59-CCG GTC GAC CGG AAG CTT CCA CAA GTG
CAT TTA-39, Reverse primer: 59-AGG CAT TCC ACC ACT
GCT CCC ATT CAT C-39. PCR conditions were 94uC for
3 min, 94uC for 30 sec, 62uC for 1 min, 72uC for 1 min, repeat
steps 2–4 for 35 cycles, 72uC for 2 min and held at 4uC. PCR
products were run on 1% agarose gel containing 16 GelRed
nucleic acid gel stain from Biotium (Hayward, CA). Stained bands
were visualized under UV light and photographed using Biorad
Gel doc EZ system (Bio-Rad, USA). Transgene positive pups were
then used for the subsequent experiments.
Pathological grading of tumor tissues
The pathological grading of TRAMP prostate cancer was
performed according to the grading system described previously
[22]. Prostate lesions in the DLP were histologically graded as
normal (duct lined with single layer of secretory epithelial cells
surrounded by two or three cell layers of fibrousmuscular stroma),
low-grade prostatic intraepithelial neoplasia (PIN) [epithelial cells
with variably elongated nuclei with condensed chromatin], high-
grade PIN (epithelial stratification and tufting, presence of
micropapillary and cribiform structures), well-differentiated carci-
noma (WDC) (epithelial cells invading fibromuscular stroma), and
moderately differentiated (MDC) to poorly differentiated (PDC)
adenocarcinoma of the prostate (sheets of neoplastic cells with little
or no glandular structures). 15 randomly selected microscopic
fields on hematoxylin and eosin (H&E) stained sections of the DLP
were scored for the incidence and pathological grade of the
prostate cancer in control and UA fed TRAMP mice.
In vivo anti-tumor study
The inbred male TRAMP mice, 4 weeks old, were maintained
in temperature controlled rooms with a 12 h light/dark cycle. All
mice were weighed before start of experiment. The mice were then
randomized into the following UA fed and control groups (n=5).
Group 1: 4 weeks old TRAMP mice were fed with UA (1% w/w)
enriched diet for 8 weeks; Group 2: 12 weeks old TRAMP mice
were fed with UA enriched diet for 6 weeks; Group 3: 24 weeks old
TRAMP mice were fed with UA enriched diet for 12 weeks.
Control TRAMP mice received normal diet. Body weight and
tumor size were recorded twice every week and the tumor size was
determined by Vernier caliper and calculated using the formula
[length6(width)
2]/2. Mice were euthanized by CO2 inhalation
followed by cervical dislocation. Blood samples, collected by
cardiac puncture, were kept at 4uC overnight and centrifuged at
10,000 rpm for 20 min to obtain serum, which was stored in
aliquots at 280uC. Tumor volume was measured and weighed.
Prostate gland was microdisected from the seminal vesicles under a
UA Modulates Tumor Growth in TRAMP Mice
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H&E and immunohistochemical analysis.
ELISA assay for TNF-a and IL-6
Stored serum samples were analyzed for TNF-a and IL-6 levels
using ELISA kit (R&D systems, USA) according to manufacturer
instructions. Sandwich ELISA protocols were used and calibration
was done with standard TNF-a and IL-6 provided in the kit.
Western blotting
Dorsolateral prostate tumor tissues were lysed in lysis buffer
containing (20 mM Tris (pH 7.4), 250 mM NaCl, 2 mM EDTA
(pH 8.0), 0.1% Triton X-100, 0.01 mg/ml aprotinin, 0.005 mg/
ml leupeptin, 1 mM PMSF, and 4 mM NaVO4). Lysates were
then centrifuged at 13,000 rpm for 10 min to remove insoluble
material and 50 mg of protein was resolved on a 10% SDS gel.
After electrophoresis, proteins were electrotransferred to a
nitrocellulose membrane, blocked with 5% nonfat milk, and
probed with antibodies of interest overnight at 4uC. The blot was
washed, exposed to HRP-conjugated secondary antibodies for 1 h,
and finally examined by chemiluminescence (ECL; GE Health-
care, Little Chalfont, Buckinghamshire, UK). Densitometric
analysis of the scanned blots was performed using Image J
software and the results are expressed as fold change relative to
control.
Immunohistochemistry
DLP tumor tissues were fixed with 10% phosphate buffered
formalin, processed and embedded in paraffin. Tissue sections,
5 mm, were cut and deparafinized as described previously [18].
Images were taken using a Olympus BX51 microscope (magni-
fication, 206). Positive cells (brown) were quantitated using The
Image-Pro plus v6.3 software package (Media Cybernetics, Inc.).
Survival studies
To investigate whether UA enriched diet can prolong the life
span of TRAMP mice, 25 male inbred TRAMP male mice were
divided into control and UA fed groups (n=5). Group 1: 4 weeks
old TRAMP mice were fed with UA enriched diet for 8 weeks;
Group 2: 12 weeks old TRAMP mice were fed with UA enriched
diet for 6 weeks; Group 3: 24 weeks old TRAMP mice were fed
with UA enriched diet for 12 weeks; Group 4: 4 week old mice
were fed with UA enriched diet for 36 weeks. Control TRAMP
mice received normal diet. Animals were monitored weekly for
body weight and tumor development by abdominal pelvic
palpation and survival.
Determination of UA in serum samples
Extraction of UA from mice serum samples were carried out by
liquid-liquid extraction (LLE) as previously described [32]. UA
concentrations in mice serum samples were then determined using
ultra performance liquid chromatography-mass spectrometry
(UPLC-MS) as previously described with modifications [33]. Mass
spectrometry data acquisition and subsequent analyses were
carried out using linear ion trap quadrupole mass spectrometer
(3200 QTRAP) equipped with a TurboIonSpray electrospray
ionization (ESI) source and Analyst 1.4.2 software (Applied
Biosystems, Foster City, CA, USA). Quantitation of analyte and
internal standard (IS) was done using single ion monitoring in
multiple reactions monitoring mode (MRM, m/z 455.0 and m/z
469.0 were used for UA and IS, respectively) (18). Representative
chromatograms are shown in Fig. 5A. The serum concentration of
UA was calculated using Analyst software 1.4.2 (Applied
Biosystem, USA).
Statistical analysis
Experiments were carried out in triplicates and repeated twice.
The significance of differences between groups was evaluated by
Student’s t-test and a p value of less than 0.05 was considered
statistically significant. Kaplan-Meier survival plots were generated
to determine the survival of mice and log-rank (Mantel-Cox) test
was performed to determine the significance difference between
control and UA fed groups.
Author Contributions
Conceived and designed the experiments: GS MKS KMH. Performed the
experiments: MKS THO CKL. Analyzed the data: MKS GS KMH PCH
PTHW. Contributed reagents/materials/analysis tools: GS APK THO
KMH. Wrote the paper: MKS PTHW GS. Critically analyzed the
manuscript: MKS PTHW GS.
References
1. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics, 2007.
CA Cancer J Clin 57: 43–66.
2. Vasto S, Carruba G, Candore G, Italiano E, Di Bona D, et al. (2008)
Inflammation and prostate cancer. Future Oncol 4: 637–645.
3. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G (2006)
Inflammation and cancer: how hot is the link? Biochem Pharmacol 72:
1605–1621.
4. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860–867.
5. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, et al. (2005)
Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 26:
1170–1181.
6. Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, et al. (1999) Lower
prostate cancer risk in men with elevated plasma lycopene levels: results of a
prospective analysis. Cancer Res 59: 1225–1230.
7. Chen L, Stacewicz-Sapuntzakis M, Duncan C, Sharifi R, Ghosh L, et al.
(2001) Oxidative DNA damage in prostate cancer patients consuming
tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst
93: 1872–1879.
8. De Marzo AM, Marchi VL, Epstein JI, Nelson WG (1999) Proliferative
inflammatory atrophy of the prostate: implications for prostatic carcinogenesis.
Am J Pathol 155: 1985–1992.
9. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, et al. (2001)
Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the
prostate, but not in prostate carcinoma. Cancer Res 61: 8617–8623.
10. Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F (2005) Nuclear
localisation of nuclear factor-kappaB transcription factors in prostate cancer: an
immunohistochemical study. Br J Cancer 93: 1019–1023.
11. Zerbini LF, Wang Y, Cho JY, Libermann TA (2003) Constitutive activation of
nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated
interleukin 6 expression in prostate cancer. Cancer Res 63: 2206–2215.
12. Okamoto M, Lee C, Oyasu R (1997) Interleukin-6 as a paracrine and autocrine
growth factor in human prostatic carcinoma cells in vitro. Cancer Res 57:
141–146.
13. Liu J (1995) Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol
49: 57–68.
14. Aggarwal BB, Shishodia S (2006) Molecular targets of dietary agents for
prevention and therapy of cancer. Biochem Pharmacol 71: 1397–1421.
15. Pathak AK, Bhutani M, Nair AS, Ahn KS, Chakraborty A, et al. (2007) Ursolic
acid inhibits STAT3 activation pathway leading to suppression of proliferation
and chemosensitization of human multiple myeloma cells. Mol Cancer Res 5:
943–955.
16. Kassi E, Sourlingas TG, Spiliotaki M, Papoutsi Z, Pratsinis H, et al. (2009)
Ursolic acid triggers apoptosis and Bcl-2 downregulation in MCF-7 breast
cancer cells. Cancer Invest 27: 723–733.
17. Zhang Y, Kong C, Zeng Y, Wang L, Li Z, et al. (2010) Ursolic acid induces PC-
3 cell apoptosis via activation of JNK and inhibition of Akt pathways in vitro.
Mol Carcinog 49: 374–385.
18. Shanmugam MK, Rajendran P, Li F, Nema T, Vali S, et al. (2011) Ursolic acid
inhibits multiple cell survival pathways leading to suppression of growth of
prostate cancer xenograft in nude mice. J Mol Med 89: 713–727.
19. Shanmugam MK, Manu KA, Ong TH, Ramachandran L, Surana R, et al.
(2011) Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to
suppression of metastasis in transgenic adenocarcinoma of mouse prostate
model. Int J Cancer 129: 1552–1563.
UA Modulates Tumor Growth in TRAMP Mice
PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e3247620. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, et al. (1997)
Androgen-independent prostate cancer progression in the TRAMP model.
Cancer Res 57: 4687–4691.
21. Garcia GE, Wisniewski HG, Lucia MS, Arevalo N, Slaga TJ, et al. (2006) 2-
Methoxyestradiol inhibits prostate tumor development in transgenic adenocar-
cinoma of mouse prostate: role of tumor necrosis factor-alpha-stimulated gene 6.
Clin Cancer Res 12: 980–988.
22. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM (1999) Pathologic
progression of autochthonous prostate cancer in the TRAMP model. Prostate
Cancer Prostatic Dis 2: 70–75.
23. Deeb D, Gao X, Liu Y, Jiang D, Divine GW, et al. (2011) Synthetic triterpenoid
CDDO prevents the progression and metastasis of prostate cancer in TRAMP
mice by inhibiting survival signaling. Carcinogenesis 32: 757–764.
24. Slusarz A, Shenouda NS, Sakla MS, Drenkhahn SK, Narula AS, et al. (2010)
Common botanical compounds inhibit the hedgehog signaling pathway in
prostate cancer. Cancer Res 70: 3382–3390.
25. Cho HJ, Park SY, Kim EJ, Kim JK, Park JH (2011) 3,39-Diindolylmethane
inhibits prostate cancer development in the transgenic adenocarcinoma mouse
prostate model. Mol Carcinog 50: 100–112.
26. Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A
(2001) Genistein in the diet reduces the incidence of poorly differentiated
prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 61:
6777–6782.
27. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H (2001) Inhibition of
prostate carcinogenesis in TRAMP mice by oral infusion of green tea
polyphenols. Proc Natl Acad Sci U S A 98: 10350–10355.
28. Singh RP, Raina K, Sharma G, Agarwal R (2008) Silibinin inhibits established
prostate tumor growth, progression, invasion, and metastasis and suppresses
tumor angiogenesis and epithelial-mesenchymal transition in transgenic
adenocarcinoma of the mouse prostate model mice. Clin Cancer Res 14:
7773–7780.
29. Singh SV, Powolny AA, Stan SD, Xiao D, Arlotti JA, et al. (2008) Garlic
constituent diallyl trisulfide prevents development of poorly differentiated
prostate cancer and pulmonary metastasis multiplicity in TRAMP mice. Cancer
Res 68: 9503–9511.
30. Singh SV, Warin R, Xiao D, Powolny AA, Stan SD, et al. (2009) Sulforaphane
inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in
association with increased cytotoxicity of natural killer cells. Cancer Res 69:
2117–2125.
31. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow?
Lancet 357: 539–545.
32. Liao Q, Yang W, Jia Y, Chen X, Gao Q, et al. (2005) LC-MS determination
and pharmacokinetic studies of ursolic acid in rat plasma after administration of
the traditional chinese medicinal preparation Lu-Ying extract. Yakugaku Zasshi
125: 509–515.
33. Xia Y, Wei G, Si D, Liu C (2011) Quantitation of ursolic acid in human plasma
by ultra performance liquid chromatography tandem mass spectrometry and its
pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 879:
219–224.
UA Modulates Tumor Growth in TRAMP Mice
PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e32476